News
Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.
2009
-
Dec 18, 2009
Prophylaxis of Influenza in Infants and Children Approved as an Additional Indication of Anti-influenza Drug Tamiflu®
[PDF 190KB] -
Dec 15, 2009
Regarding the Incidence of Insider Trading on Chugai Stock
[PDF 21KB] -
Dec 10, 2009
Organizational Restructuring and Personnel Changes
[PDF 83KB] -
Dec 04, 2009
Conclusion of a license agreement between BioComber and Chugai on patents related to PURESYSTEM®
[PDF 40KB] -
Nov 28, 2009
Regarding Today's Media Reporting
[PDF 21KB] -
Nov 25, 2009
Chugai Revises Corporate Advertisement for First Time in Four Years
[PDF 248KB] -
Nov 20, 2009
ACTEMRA Improves Signs and Symptoms in Children with Systemic Onset Juvenile Idiopathic Arthritis (sJIA)
[PDF 100KB] -
Nov 19, 2009
Recombinant Human Erythropoietin, Epogin® Injection
Application for Approval of Additional Indication of Chemotherapy-Induced Anemia
[PDF 172KB] -
Nov 12, 2009
Chugai Presents an Anti-Cancer Charity Concert, "Christmas Concert in Yokohama Featuring Star Philharmonic Chorus"
[PDF 656KB] -
Nov 11, 2009
Chugai Presents
"Volunteer for Life: Jose Carreras Christmas Concert" as the Special Co-Sponsor
[PDF 172KB] -
Nov 09, 2009
Anti-Malignancy Agent Avastin®
Obtained Approval for Additional Indication of Non-Small Cell Lung Cancer
[PDF 76KB] -
Nov 06, 2009
Notice Concerning the Passing Away of a Chugai Pharmaceutical Director
[PDF 172KB] -
Oct 22, 2009
New Drug Application Filed for Eldecalcitol, An Active Vitamin D3 Derivative
[PDF 46KB] -
Oct 19, 2009
ACTEMRA inhibits progression of joint destruction in RA patients by over 80% compared to methotrexate alone
[PDF 69KB] -
Oct 16, 2009
Anti-Malignancy Agent/Anti-VEGF Humanized Monoclonal Antibody, Avastin®
Application for Approval of Additional Indication of Breast Cancer
[PDF 52KB] -
Oct 15, 2009
F. Hoffmann-La Roche Announces Third Quarter Sales 2009
[PDF 26KB] -
Oct 07, 2009
Revision of Financial Outlook for Fiscal Year 2009
(January 1 - December 31, 2009)
[PDF 47KB] -
Oct 05, 2009
Contribution of Para-transit Vehicles to Welfare Services
[PDF 103KB] -
Oct 01, 2009
Establishment of the Chugai Academy for Advanced Oncology (CHAAO)
- Elevating Japan's cancer treatment to a global level - [PDF 53KB] -
Sep 30, 2009
RoACTEMRA filed in Europe for the Inhibition of Joint Damage and Improvement in Physical Function in Rheumatoid Arthritis
[PDF 59KB] -
Sep 24, 2009
Anti-Cancer Agent Xeloda® and Avastin®
Obtained Approval for Additional Indication of Colorectal Cancer
[PDF 61KB] -
Sep 18, 2009
Antineoplastic Agent / Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor, Tarceva®
Application for Approval of Additional Indication of Pancreatic Cancer
[PDF 53KB] -
Sep 18, 2009
Chugai Displays, "Giant Colon", A Giant Size Balloon Art at "Relay for Life 2009"
[PDF 94KB] -
Sep 15, 2009
Organizational Restructuring and Personnel Changes
[PDF 130KB] -
Sep 07, 2009
Supply Plan of "Tamiflu®" Anti-influenza Drug
[PDF 71KB] -
Aug 31, 2009
Reconstruction Support for Devastating Typhoon Disaster Area in the Republic of China
[PDF 171KB] -
Aug 19, 2009
Organizational Restructuring and Personnel Changes
[PDF 84KB] -
Jul 31, 2009
Update on FDA Registration of Actemra®, a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody for Rheumatoid Arthritis
[PDF 28KB] -
Jul 23, 2009
F. Hoffmann-La Roche Announces 2009 Half Year Results
[PDF 70KB] -
Jul 22, 2009
Chugai Files NDA for a Renal Anemia Agent R744
[PDF 20KB] -
Jun 30, 2009
Primary Endpoint Achieved in Phase III Clinical Trial of Epogin® in Chemotherapy Induced Anemia
[PDF 22KB] -
Jun 11, 2009
New Developments for "CHUGAI ONCOLOGY": Establishment of "Cancer Information Guide," a Website for Patients
[PDF 855KB] -
May 11, 2009
Determination of Terms and Conditions of Stock Options as Stock-based Compensation (Stock Acquisition Rights)
[PDF 16KB] -
Apr 24, 2009
Chugai to Absorb Wholly-Owned Subsidiary
[PDF 41KB] -
Apr 24, 2009
Issuance of Stock Options as Stock-based Compensation(Stock Acquisition Rights)
[PDF 36KB] -
Apr 22, 2009
Approval of Partial Change of API Manufacturing Method and Pharmaceutical Formulation of the Recombinant Human Erythropoietin "Epogin® Injection"
[PDF 52KB] -
Apr 16, 2009
F. Hoffmann-La Roche Announces First Quarter Sales 2009
[PDF 17KB] -
Apr 09, 2009
Determination of Terms and Conditions of Common Stock Options (Stock Acquisition Rights)
[PDF 36KB] -
Mar 25, 2009
Notice of Issuance of Common Stock Options (Stock Acquisition Rights)
[PDF 52KB] -
Mar 25, 2009
Relationship with the Parent Companies and Related Parties
[PDF 127KB] -
Feb 18, 2009
License Agreement with Romark Laboratories and Development of Nitazoxanide in Japan
[PDF 131KB] -
Feb 04, 2009
Notification Concerning Dividend Distribution
[PDF 43KB] -
Feb 04, 2009
Appointments of a New Director and an Auditor
[PDF 61KB] -
Feb 04, 2009
Abolishment of Directors' Retirement Benefits and Granting of Stock Options
[PDF 37KB] -
Feb 04, 2009
F. Hoffmann-La Roche Announces Financial Results for Fiscal 2008
[PDF 68KB] -
Jan 23, 2009
Loss of personal information as a result of having a sales vehicle stolen
[PDF 72KB] -
Jan 21, 2009
RoACTEMRA®, a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody, Approved in EU for Rheumatoid Arthritis
[PDF 64KB]
